72886-5

LOINC code 72886-5 identifies "CYP2D6 gene and CYP2C19 gene targeted mutation analysis panel - Blood or Tissue by Molecular genetics method". CYP2D6 and CYP2C19 cytochrome P450 genes play a major role in the metabolism of many widely prescribed drugs, including anti-depressants, anti-psychotics, anti-epileptics, proton pump inhibitors, and beta-blockers. The CYP2D6 gene has at least 70 allelic variants resulting in four phenotypic types: poor metabolizers with gene inactivation of both alleles, intermediate metabolizers with one reduced activity allele and one null allele, extensive metabolizers with at least one functional allele, and ultra-rapid metabolizers with excess enzymatic activity due to multiple copies of functional alleles from gene duplication. The CYP2C19 gene has two major variant alleles that result in enzyme deficiency. This panel term is created for, but not limited to, Roche Diagnostics' AmpliChip CYP450 assay, which detects 29 polymorphisms in the 2D6 and 2 polymorphisms in the 2C19 gene, as well as gene duplications and deletions.

This code measures CYP2D6 gene & CYP2C19 gene targeted mutation analysis panel in Bld/Tiss. It belongs to the PANEL.MOLPATH.PHARMG class in the LOINC classification.

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.